JJ - the US Army Medical Research Institute of Infectious Diseases (USAMRIID) is going to be there, including the woman who is heading up the CYGX collaboration, Dr. Connie Schamaljohn.
This was the CYGX PR in March:
CytoGenix and USAMRIID to Collaborate in Developing Biodefense synDNA™ Vaccines
Houston, TX (27 March 2007) CytoGenix, Inc. (CYGX.OB) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
Scientists from CytoGenix and USAMRIID, led by Dr. Connie Schmaljohn, intend to develop and test synDNA™ vaccines for the prevention of disease caused by the Ebola virus and several strains of equine encephalitis viruses.
Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, stated, "We are pleased to have the opportunity to work with Dr. Schmaljohn and the USAMRIID team at Fort Detrick. These disease targets are listed as Category A & B bioterrorism agents/diseases by the Centers for Disease Control. Data collected under this CRADA will help to demonstrate the validity of use of synDNA™ vaccines in rapid response platforms including the protection of our nation's military personnel, health providers and other first responders, as well as the general population against a spectrum of existing and emerging terroristic and other infectious diseases."
AI
